2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1
  5. PD-1/PD-L1 Agonist

PD-1/PD-L1 Agonist

PD-1/PD-L1 Agonists (5):

Cat. No. Product Name Effect Purity
  • HY-P9S0062
    Rosnilimab (Mouse IgG2a)
    		Agonist 98.0%
    Rosnilimab (Mouse IgG2a) is a mouse-derived IgG2a, Rosnilimab. Rosnilimab is a PD-1 agonistic monoclonal antibody. Rosnilimab (Mouse IgG2a) can be used in research related to ulcerative colitis.
  • HY-P9997
    Rosnilimab
    		Agonist 99.19%
    Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis.
  • HY-P10908
    H-20
    		Agonist 99.55%
    H-20 is a PD-1 agonist. H-20 can be used in the research of chronic pain.
  • HY-P991351
    RTX-002
    		Agonist
    RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. RTX-002 can be used to study autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.
  • HY-P992062
    Anti-Mouse CD80 Antibody (TKMG48)
    		Agonist
    Anti-Mouse CD80 Antibody (TKMG48) is an antibody that targets mouse CD80. By specifically binding to and disrupting the CD80:PD-L1 complex to release PD-L1, Anti-Mouse CD80 Antibody (TKMG48) functions as an indirect PD-1 agonist without blocking CD28 co-stimulation or CD80-CTLA4 binding. Anti-Mouse CD80 Antibody (TKMG48) inhibits T cell activation, reduces T cell effector functions and antigen-specific CD8+ T cell populations, and does not interfere with the differentiation, migration, antigen presentation or surface marker expression of dendritic cells. Anti-Mouse CD80 Antibody (TKMG48) significantly attenuates disease severity in mouse models of arthritis, spondyloarthritis, multiple sclerosis and Sjögren's syndrome, and its activity depends on the expression of PD-1 and PD-L1.